ArticleEye (London, England)2025
Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond drug price: A comparison of overall costs of anti-vascular endothelial growth factor therapy alternatives for neovascular age-related macular degeneration in Norway.Acta ophthalmologica · 2026Article
- Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg.Journal of ophthalmology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesSustainability is a major concern with the use of intravitreal therapy for neovascular age-related macular degeneration (nAMD), as case numbers rise with the ageing population. The aim of this study is to quantify the difference in the carbon emissions from factory gate to patient between aflibercept 2 mg pre-filled syringe (PFS) and aflibercept 8 mg PFS when used over the first 2 years in treatment-naïve patients with nAMD in the UK.
methodsThe carbon footprint per injection was calculated by adding carbon emissions-obtained from internal corporate and published data-for packaging creation, transport, patient travel and waste disposal for each product. Results were extrapolated to a UK population using an estimate of the number of injections from real-world evidence and/or clinical trial data and the published incidence of nAMD.
resultsBetween factory and patient, the carbon emissions for aflibercept 2 mg PFS are approximately 2.3 kg CO
conclusionsUsing aflibercept 8 mg PFS instead of aflibercept 2 mg PFS in treatment-naïve patients with nAMD has benefits for the environment and National Health Service (NHS) capacity and would therefore help meet NHS sustainability goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.